Clinical trial
Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia
NCT00409201 · Abarbanel Mental Health Center, Other · Unknown status
Key facts
| NCT number | NCT00409201 |
|---|---|
| Title | Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia |
| Official title | Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures |
| Lead sponsor | Abarbanel Mental Health Center, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | reboxetine adjuvant therapy |
| Enrollment | 30 |
| Start date | Mar 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Dec 8, 2006 |
| Last update posted | Dec 8, 2006 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: